A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Thomas Martin, Rachid Baz, Don M Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana, Ravi Vij, Thomas Martin, Rachid Baz, Don M Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana, Ravi Vij

Abstract

This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for 4 weeks and then Q2W thereafter [QW/Q2W]), in combination with lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM). Patients received 28-day treatment cycles; the primary objective was to determine the maximum tolerated dose (MTD) of isatuximab with lenalidomide and dexamethasone. Fifty-seven patients (median 5 [range 1-12] prior regimens; 83% refractory to previous lenalidomide therapy) were treated. Median duration of dosing was 36.4 weeks; 15 patients remained on treatment at data cutoff. Isatuximab-lenalidomide-dexamethasone was generally well tolerated with only 1 dose-limiting toxicity reported (grade 3 pneumonia at 20 mg/kg QW/Q2W); the MTD was not reached. The most common isatuximab-related adverse events were infusion-associated reactions (IARs) (56%), which were grade 1/2 in 84% of patients who had an IAR and predominantly occurred during the first infusion. In the efficacy-evaluable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts. The ORR was 52% in 42 evaluable lenalidomide-refractory patients. Overall median progression-free survival was 8.5 months. Isatuximab exposure increased in a greater than dose-proportional manner; isatuximab and lenalidomide pharmacokinetic parameters appeared independent. These data suggest that isatuximab combined with lenalidomide and dexamethasone is active and tolerated in heavily pretreated patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT01749969.

© 2017 by The American Society of Hematology.

Figures

Figure 1.
Figure 1.
IARs by grade and infusion number. IARs during first infusion or after first infusion are displayed for each dose, according to initial infusion rate. No IARs were observed after the fourth infusion.
Figure 2.
Figure 2.
IMWG response overall and by dose: efficacy evaluable population. sCR, stringent complete response.
Figure 3.
Figure 3.
Response rate by previous anticancer therapy, including response by prior regimen or number of prior lines of treatment: efficacy evaluable population. No., number; rel, relapsed; refr, refractory.
Figure 4.
Figure 4.
Kaplan-Meier analysis of PFS. Median PFS (95% CI) (months) is plotted for each dose cohort and the total population. NR, not reached.

References

    1. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am Soc Hematol Educ Program. 2012;2012:354-361.
    1. Eshaghian S, Berenson JR. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care. 2012;6(3):330-336.
    1. Palumbo A, Hajek R, Delforge M, et al. ; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
    1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
    1. San-Miguel JF, Hungria VT, Yoon SS, et al. . Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016;3(11):e506-e515.
    1. Siegel DS, Dimopoulos M, Jagannath S, et al. . VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory mulltiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(6):329-334.
    1. Kumar SK, Lee JH, Lahuerta JJ, et al. ; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [published correction appears in Leukemia. 2012;26(5):1153]. Leukemia. 2012;26(1):149-157.
    1. Moreau P, Masszi T, Grzasko N, et al. ; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634.
    1. Janssen Biotech, Inc. Highlights of prescribing information: DARALEX (daratumumab) injection, for intravenous use. . Accessed 30 January 2017.
    1. Darzalex: EPAR–Summary of Product Characteristics. . Accessed 30 January 2017.
    1. Bristol-Myers Squibb Company. Highlights of prescribing information: EMPLICITI (elotuzumab) for injection, for intravenous use. Available at: . Accessed 30 January 2017.
    1. Empliciti: EPAR–Summary of Product Characteristics. . Accessed 30 January 2017.
    1. Lonial S, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2016;16(10):1291-1301.
    1. Lonial S, Dimopoulos M, Palumbo A, et al. ; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
    1. Lonial S, Weiss BM, Usmani SZ, et al. . Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
    1. Palumbo A, Chanan-Khan A, Weisel K, et al. ; CASTOR Investigators. Daratumumab, bortezomib and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766.
    1. Dimopoulos MA, Oriol A, Nahi H, et al. ; POLLUX Investigators. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331.
    1. Roguska MA, Pedersen JT, Keddy CA, et al. . Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA. 1994;91(3):969-973.
    1. Deckert J, Wetzel MC, Bartle LM, et al. . SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574-4583.
    1. Martin T, Richter J, Vij R, et al. . A dose finding phase II trial of isatuximabtuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma [abstract]. Blood. 2015;126(23). Abstract 509.
    1. Durie BG, Harousseau JL, Miguel JS, et al. ; International Myeloma Working Group. International uniform response criteria for multiple myeloma [published correction appears in Leukemia. 2006;21:1134; Leukemia. 2006;20(12):2220]. Leukemia. 2006;20(9):1467-1473.
    1. Hann B, Cai T, Wang D, et al. SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma. In: Proceedings from the American Association for Cancer Research (AACR) Annual Meeting; 6-10 April 2013; Washington, DC. Poster No. 5469.
    1. Xu Y, Sun J, Sheard MA, et al. . Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother. 2013;62(10):1637-1648.
    1. Mitsiades CS, Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2013;88(suppl 1):S5-S13.
    1. Chan AC, Neeson P, Leeansyah E, et al. . Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol. 2014;175(1):49-58.
    1. Rajkumar SV, Harousseau JL, Durie B, et al. ; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
    1. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601-609.
    1. João C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. Ann Hematol. 2015;94(1):97-105.
    1. Dimopoulos MA, Swern AS, Li JS, et al. . Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2014;4:e257.
    1. Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(5):e64354.
    1. Dimopoulos M, Spencer A, Attal M, et al. ; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
    1. Weber DM, Chen C, Niesvizky R, et al. ; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-2142.
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
    1. San Miguel J, Weisel K, Moreau P, et al. . Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
    1. Richardson PG, Jagannath S, Moreau P, et al. ; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516-e527.
    1. Plesner T, Arkenau H-T, Gimsing P, et al. . Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128:1821-1828.
    1. Usmani SZ, Dimopoulos M, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of POLLUX [abstract]. Blood. 2016;128(22). Abstract 1151.
    1. Martin T, Strickland S, Glenn M, Hsu K, Charpentier E, Mikhael J A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. In: Proceedings from the American Society of Clinical Oncology (ASCO) Annual Meeting; 30 May-3 June 2014; Chicago, IL. Poster No. 8532.
    1. Celgene Corporation. REVLIMID 5 AND 10 mg capsules: Clinical pharmacology and biopharmaceutics NDA review. . Accessed 22 June 2016.
    1. Vij R, Lendvai N, Martin TG, et al. A phase 1b dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory MM (RRMM): interim results from two new dose cohorts. In: Proceedings from the American Society of Clinical Oncology (ASCO) Annual Meeting; 3-7 June 2016; Chicago, IL. Abstract 8009.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다